PRKDC and neoplasm: While these findings collectively support that inhibitors of the DNA damage response enhance the radiation-induced innate immune response in tumor cells, it is likely, given the differential abilities of ATM, ATR, and DNA-PK to modulate DNA repair, replication stress, and cell cycle checkpoints, that therapies targeting these proteins will also vary in terms of their ability to induce antitumoral immunity.